Weekly Incretin Analog Dose Escalation for GI Tolerability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for type 2 diabetes mellitus (T2DM) and obesity using GCG, GLP-1, and GIP triple receptor agonists face challenges with gastrointestinal adverse events and require multiple weeks to reach steady state activity, limiting efficacy and patient compliance.
Innovation Solution
Optimized doses and dosing regimens for a GGG tri-receptor agonist (SEQ ID NO:1) ranging from 0.5 mg to 12.0 mg, administered weekly with incremental adjustments, to improve glycemic control and weight management while minimizing adverse events.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of GGG tri-receptor agonist are administered to achieve effective glycemic control and weight management, then therapeutic efficacy is improved, but gastrointestinal adverse events increase
Solution Approach 1:
The patent divides the dosing regimen into multiple stages: an initial low dose (0.25-2 mg) for the first week, followed by intermediate doses (2-4 mg), and finally higher maintenance doses (4-12 mg). This segmentation allows the body to gradually adapt to the medication, reducing gastrointestinal adverse events while ultimately achieving effective glycemic control and weight management
Solution Approach 2:
The patent implements a preliminary low-dose exposure phase before escalating to therapeutic doses. By administering 0.25-2 mg during the first week, the body is prepared for subsequent higher doses, minimizing the occurrence and severity of gastrointestinal side effects that would otherwise limit effective treatment
2Ease of operation
If once-weekly dosing is used to reduce injection frequency and improve compliance, then ease of operation is improved, but time to reach steady state activity increases
Solution Approach 1:
The patent administers multiple low-dose injections during the first week (on day 1 and day 7) before transitioning to once-weekly dosing. This preliminary action ensures that therapeutic levels are achieved more quickly while maintaining the convenience of once-weekly administration, reducing the time to reach steady state without increasing injection burden
3Reliability
If dose escalation is implemented to overcome gastrointestinal tolerance limits, then therapeutic efficacy is improved, but patient compliance may deteriorate
Solution Approach 1:
The patent segments the dose escalation process into clearly defined phases with specific dose ranges for each phase. This structured approach makes it easier for patients to understand and adhere to the treatment plan, as they know what to expect at each stage, thereby maintaining compliance while achieving effective doses
Solution Approach 2:
The patent incorporates monitoring of gastrointestinal adverse events and glycemic control at each dosing stage. This feedback mechanism allows for individualized dose adjustments, ensuring that patients receive the minimum effective dose needed to achieve therapeutic goals while minimizing side effects, thereby maintaining long-term compliance
Data Source
AI summary
Doses and dosing regimens for incretin analogs are disclosed comprising determining and administering doses of long-acting incretin analogs suitable for once-weekly dosing, such as a glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) (GGG) tri-receptor agonist.